Peptide Synthesis: Physiology and What Research Reports

What "peptide synthesis" means

The phrase peptide synthesis is used in two different settings, and readers meet both. In physiology, it refers to the way living cells assemble amino acids into peptide chains and then process those chains into biologically active molecules. In chemistry and pharmaceutical science, it refers to the laboratory construction of a defined peptide sequence, one amino acid at a time, using protecting-group chemistry and coupling reagents. Almost all of the published methodological literature — including the papers summarised below — concerns the second sense.

Both senses share a core chemical event: the formation of an amide (peptide) bond between the carboxyl group of one amino acid and the amino group of the next. What differs is the machinery. Cells use ribosomes, transfer RNA and enzymatic processing; laboratories use resins, activated esters and orthogonal protecting groups.

Where peptides are made in the body

In the biological sense, peptide synthesis begins in the cytoplasm, where ribosomes translate messenger RNA into a polypeptide chain. Peptides destined for secretion — hormones, neuropeptides, growth factors — are typically made first as larger precursor proteins. These precursors move through the endoplasmic reticulum and Golgi apparatus, where signal sequences are removed, disulfide bonds form, and processing enzymes cleave the precursor into smaller fragments. Further modifications, such as amidation of the C-terminus or glycosylation, can occur before the finished peptide is packaged into secretory vesicles and released.

This is why many endogenous peptides exist in multiple forms: a prohormone, one or more intermediate fragments, and a mature signalling peptide. It is also why the same gene can give rise to several distinct peptide products depending on which processing enzymes a given tissue expresses. Understanding this sequence helps explain why laboratory-made analogues are often designed with modifications — such as substituted or protected residues — intended to resist the same enzymes that normally clear or truncate the natural molecule.

How laboratories build peptides

The dominant laboratory approach is solid-phase peptide synthesis (SPPS), in which the growing chain stays anchored to an insoluble resin so that excess reagents and by-products can simply be washed away between steps. Protocol chapters describing Fmoc solid-phase peptide synthesis set out this stepwise cycle of deprotection, coupling and washing, and an updated 2024 chapter on Fmoc solid-phase peptide synthesis described the same framework for current practice.

A 2016 review in the Journal of Peptide Science surveyed advances in Fmoc solid-phase peptide synthesis, and researchers have continued to refine the cycle since. Protecting groups are central to the process, because every amino acid carries reactive side chains that must be kept inert until the chain is complete; a dedicated 2020 chapter reviewed protecting groups in peptide synthesis and their role in orthogonal strategies.

Automation, scale and miniaturisation

Because the SPPS cycle is repetitive, it lends itself to machines. A 2020 Methods in Molecular Biology chapter described automated solid-phase peptide synthesis as a standard laboratory workflow, and a 2025 chapter described an ultra-efficient solid-phase peptide synthesis approach. At the other end of the scale, a 2024 paper reported solid-phase peptide synthesis in 384-well plates, a format suited to making large numbers of short sequences in parallel rather than a single large batch.

Newer coupling chemistry

Forming the amide bond efficiently, without racemising the amino acid or leaving deletion sequences behind, remains an active research problem. A 2024 paper in Chemistry described twisted amide-mediated peptide synthesis, and a 2023 Organic Letters report described 4-iodine N-methylpyridinium-mediated peptide synthesis as an alternative activation strategy. A broad 2025 review in Biofabrication covered classical and emerging methods across the field, placing solution-phase, solid-phase and newer approaches side by side.

Specialised products

Not every synthesis targets a natural sequence. A 2019 paper in the Journal of Labelled Compounds and Radiopharmaceuticals described the synthesis of carbon-14-labelled peptides, the kind of material used in tracer and metabolism studies rather than as a therapeutic. A 2025 chapter described the synthesis of polymyxin-inspired peptidomimetics, illustrating how chemists build molecules that imitate a peptide scaffold while departing from natural amino acids.

Approaches described in the literature

Purity, by-products and method limits: What Studies Report

Synthesis literature is candid that the process is imperfect. Because each cycle is less than 100% efficient, long or aggregation-prone sequences accumulate truncated and deletion by-products, and side-chain protecting groups can generate additional impurities during cleavage. The 2016 review of advances in Fmoc SPPS was written around exactly these difficulties, and the 2020 chapter on protecting groups reported that the choice of orthogonal protection strategy shapes which side reactions are possible. The 2025 Biofabrication review of classical and emerging methods compared approaches in terms of their practical trade-offs. None of these papers is a clinical study, and none reports human safety outcomes; a synthesised peptide's purity profile is a manufacturing question, while its biological effects are established — or not — in separate pharmacological and clinical work.

Why the term matters to readers

Readers encounter "peptide synthesis" in three common contexts: biology coursework describing translation and prohormone processing; certificates of analysis and research-use-only labelling, where a synthesis route and purity figure are quoted; and drug-development news, where synthesis cost and scalability influence whether a peptide candidate advances. Knowing that the term can mean either a cellular process or a bench procedure prevents a common confusion — a molecule described as "synthetic" is not necessarily different in sequence from the endogenous one, and a molecule described as "peptidomimetic", as in the polymyxin-inspired work (PMID 40531465), may deliberately differ from any natural peptide.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medical question. Nothing here describes a protocol, and the cited work is chemistry and methodology literature rather than treatment research.

References

• Advances in Fmoc solid-phase peptide synthesis (Journal of Peptide Science, 2016)
• Fmoc Solid-Phase Peptide Synthesis (Methods in Molecular Biology, 2015)
• Peptide synthesis: a review of classical and emerging methods (Biofabrication, 2025)
• Twisted Amide-Mediated Peptide Synthesis (Chemistry, 2024)
• Fmoc Solid-Phase Peptide Synthesis (Methods in Molecular Biology, 2024)
• Automated Solid-Phase Peptide Synthesis (Methods in Molecular Biology, 2020)
• Protecting Groups in Peptide Synthesis (Methods in Molecular Biology, 2020)
• Ultra-Efficient Solid-Phase Peptide Synthesis (Methods in Molecular Biology, 2025)
• Synthesis of carbon-14-labelled peptides (Journal of Labelled Compounds and Radiopharmaceuticals, 2019)
• Solid-phase peptide synthesis in 384-well plates (Journal of Peptide Science, 2024)
• 4-Iodine N-Methylpyridinium-Mediated Peptide Synthesis (Organic Letters, 2023)
• Synthesis of Polymyxin-Inspired Peptidomimetics (Methods in Molecular Biology, 2025)